Key result
Black race is linked to ~21% higher in-hospital mortality among patients hospitalized with sarcoidosis.
Why the study?
Recent trends of hospitalizations, in-hospital mortality, prevalence of cardiovascular manifestations, and rates of implantable cardioverter-defibrillator implantation in sarcoidosis were not well defined.
What are the temporal trends in hospitalization rates, cardiovascular manifestations, device utilization, and racial disparities in in-hospital mortality among patients hospitalized with sarcoidosis in the United States?
Cohort (n=609,051)
Yes
What are the temporal trends in hospitalization rates, cardiovascular manifestations, device utilization, and racial disparities in in-hospital mortality among patients hospitalized with sarcoidosis in the United States?
Answers are grounded in this paper and cite their sources.
Cardiovascular manifestations occur in nearly one-third of sarcoidosis hospitalizations (predominantly heart failure and arrhythmias), yet ICD utilization remains static and low, and Black patients experience significantly higher rates of in-hospital cardiac arrest and mortality.
Background Recent trends of hospitalizations and in‐hospital mortality are not well defined in sarcoidosis. We examined aforementioned trends and prevalence of cardiovascular manifestations and explored rates of implantable cardioverter‐defibrillator implantation in hospitalizations with sarcoidosis. Methods and Results Using data from the National Inpatient Sample, a retrospective population cohort from 2005 to 2014 was studied. To identify sarcoidosis, an International Classification of Diseases, Ninth Revision, Clinical Modification ( ICD‐9‐CM ) diagnosis code was used. We excluded hospitalizations with myocardial infarction, coronary artery disease, and ischemic cardiomyopathy. Cardiovascular manifestations were defined by the presence of diagnosis codes for conduction disorders, arrhythmias, heart failure, nonischemic cardiomyopathy, and pulmonary hypertension. A total of 609 051 sarcoidosis hospitalizations were identified, with an age of 55±14 years, 67% women, and 50% black. The number of sarcoidosis hospitalizations increased from 2005 through 2014 (138 versus 175 per 100 000, P trend <0.001). We observed declining trends of unadjusted in‐hospital mortality (6.5 to 4.9 per 100 sarcoidosis hospitalizations, P trend <0.001). Overall ≈31% (n=188 438) of sarcoidosis hospitalizations had coexistent cardiovascular manifestations of one or more type. Heart failure (≈16%) and arrhythmias (≈15%) were the most prevalent cardiovascular manifestations. Rates of implantable cardioverter‐defibrillator placement were ≈7.5 per 1000 sarcoidosis hospitalizations ( P trend =0.95) during the study period. Black race was associated with 21% increased risk of in‐hospital mortality (odds ratio, 1.21; 95% confidence interval, 1.16–1.27 [ P <0.001]). Conclusions Sarcoidosis hospitalizations have increased over the past decade with a myriad of coexistent cardiovascular manifestations. Black race is a significant predictor of in‐hospital mortality, which is declining. Further efforts are needed to improve care in view of low implantable cardioverter‐defibrillator rates in sarcoidosis.
No takes yet. Share an insight, caveat, or question.
Patel et al. (2018) conducted a cohort in Sarcoidosis hospitalizations (n=609,051). Black race (and 2005-2014 hospitalization trends in sarcoidosis) vs. White race (reference group) was evaluated on In-hospital mortality (OR 1.21, 95% CI 1.16-1.27, p=<0.001). Black race was associated with a 21% increased risk of in-hospital mortality among sarcoidosis hospitalizations, while overall mortality declined from 6.5% to 4.9%.
Synapse has enriched 10 related papers. Consider them for comparative context: